Intuitive Surgical Reports 21% Revenue Growth for 2025

Reuters
01/14
Intuitive Surgical Reports 21% Revenue Growth for 2025

Intuitive Surgical Inc. announced preliminary, unaudited financial and operational results for the fourth quarter and full year 2025. Worldwide procedures using the company’s da Vinci and Ion platforms grew approximately 18% compared to the fourth quarter of 2024, with da Vinci procedures increasing by 17% and Ion procedures by 44%. Average da Vinci system utilization rose by 4% year-over-year in the fourth quarter, attributed primarily to increased adoption of the da Vinci 5 system in the U.S. and growth in markets outside the U.S. During 2025, Intuitive placed 1,721 da Vinci surgical systems, up from 1,526 in 2024. Of these, 870 were da Vinci 5 systems, compared to 362 in 2024. The company placed 195 Ion endoluminal systems in 2025, compared to 271 in the prior year. Preliminary revenue for the fourth quarter of 2025 was approximately $2.87 billion, representing a 19% increase from $2.41 billion in the same period of 2024. Preliminary full-year revenue for 2025 was approximately $10.06 billion, a 21% increase from $8.35 billion in 2024. Fourth quarter 2025 expenses included a $70 million contribution to the Intuitive Foundation, compared to $45 million in the fourth quarter of 2024. The company reported that more than 3.1 million da Vinci procedures were performed during 2025. Additional unaudited preliminary revenue and procedure information is available in the Investor Relations section of the Intuitive website. The company plans to discuss full financial results in detail during its scheduled conference call on January 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intuitive Surgical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9625439-en) on January 14, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10